Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

Investigational New Drugs

Volumn 23, Issue 4, 2005, Pages 331-337

  Sugiura, Takahiko ^a   Ariyoshi, Yutaka ^a   Negoro, Shunichi ^b   Nakamura, Shinichiro ^c   Ikegami, Harumichi ^c   Takada, Minoru ^d   Yana, Takashi ^d   Fukuoka, Masahiro ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

Advanced non small cell lung cancer; Amrubicin; Anthracycline; Chemotherapy

Indexed keywords

AMRUBICIN; ANTHRACYCLINE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYTOLOGY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOXICITY; ECG ABNORMALITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HEMATEMESIS; HEMOGLOBINOPATHY; HISTOLOGY; HUMAN; INJECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MEASUREMENT; MELENA; NAUSEA; NEUTROPENIA; ORGAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; POPULATION; PRIORITY JOURNAL; PROTEINURIA; STOMATITIS; THROMBOCYTOPENIA; VISUAL DISORDER; VITREOUS DISEASE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE II; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS;

EID: 22144481239     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-1441-3     Document Type: Article

References (16)

1. Ishizumi K, Ohashi N, Tanno N: Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52: 4477-4485, 1987
2. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M: Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80: 69-76, 1989
3. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M: Toxicological aspects of a novel 9-aminoanthracyline, SM-5887. Jpn J Cancer Res 80: 77-82, 1989
4. Suzuki T, Minamida S, Iwasaki T, Yamamoto H, Kanda H: Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. Invest New Drugs 15: 219-225, 1997
5. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxombicin-induced cardiomyopathy in dogs. Invest New Drugs 16: 121-128, 1998
6. Hiraki S, Shinkai T, Furuse K, Fukuoka M, Ohnoshi T, Kimura I, The SM-5887 lung cancer study group: A phase II study of SM-5887, a novel 9-aminoanthracycline, for non-small-cell lung cancer. Proceedings of the 18th International Congress of Chemotherapy 866-867, 1993
7. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y: Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89: 1067-1073, 1998
8. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y: In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89: 1055-1060, 1998
9. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y: Evaluation of amrubicin with a 5 day administration schedule in a mouse model. Jpn J Cancer Res 26: 1305-1312.
10. Feld R, Wierzbicki R, Walde PL, Shepherd FA, Gupta S, Shannon P, Lassus M: Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol 10: 297-303, 1992.
11. Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101-130, 1993.
12. World Health Organization: Handbook for Reporting Results of Cancer Treatment (WHO Offst Publication No. 48). Geneva, Switzerland, World Health Organization, 1979.
13. Ginsberg RJ, Vokes EE, Raben A: Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th ed. New York, NY, 1997: 858-911.
14. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 5: 1087-1100, 1998
15. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89: 1229-1238, 1998
16. Inoue K, Ogawa M, Horikoshi N, Mukaiyama T, Itoh Y, Imajoh K, Ozeki H, Nagamine D, Shinagawa K: Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative. Invest New Drugs 7: 213-218, 1989